Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2002-4-29
pubmed:abstractText
To review preclinical and clinical information on flavopiridol, an inhibitor of cyclin-dependent kinases (CDKs), tested as an antitumor agent.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1060-0280
pubmed:author
pubmed:issnType
Print
pubmed:volume
36
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
905-11
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:11978170-Antineoplastic Agents, pubmed-meshheading:11978170-Clinical Trials, Phase I as Topic, pubmed-meshheading:11978170-Clinical Trials, Phase II as Topic, pubmed-meshheading:11978170-Colonic Neoplasms, pubmed-meshheading:11978170-Cyclin-Dependent Kinases, pubmed-meshheading:11978170-Diarrhea, pubmed-meshheading:11978170-Drug Evaluation, Preclinical, pubmed-meshheading:11978170-Drug Therapy, Combination, pubmed-meshheading:11978170-Fatigue, pubmed-meshheading:11978170-Flavonoids, pubmed-meshheading:11978170-Humans, pubmed-meshheading:11978170-Infusion Pumps, pubmed-meshheading:11978170-Kidney Neoplasms, pubmed-meshheading:11978170-Lymphoma, Non-Hodgkin, pubmed-meshheading:11978170-Neoplasms, pubmed-meshheading:11978170-Neutropenia, pubmed-meshheading:11978170-Piperidines
pubmed:year
2002
pubmed:articleTitle
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
pubmed:affiliation
Center for Cancer Research, National Cancer Institute, Building 10 Room 5A01, 9000 Rockville Pike, Bethesda, MD 20892, USA.
pubmed:publicationType
Journal Article, Review